The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02632760




Registration number
NCT02632760
Ethics application status
Date submitted
7/12/2015
Date registered
17/12/2015

Titles & IDs
Public title
Intravenous Iron for Treatment of Anaemia Before Cardiac Surgery
Scientific title
Intravenous Iron for Treatment of Anaemia Before Cardiac Surgery
Secondary ID [1] 0 0
605/15
Universal Trial Number (UTN)
Trial acronym
ITACS
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Anaemia 0 0
Condition category
Condition code
Blood 0 0 0 0
Anaemia

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Ferric carboxymaltose
Treatment: Drugs - Placebo

Active comparator: ferric carboxymaltose - ferric carboxymaltose 1000 mg or Iron isomaltoside 1000 mg given Intravenously

Placebo comparator: Placebo - Placebo intravenous infusion


Treatment: Drugs: Ferric carboxymaltose
treatment for Iron deficient anaemia

Treatment: Drugs: Placebo
placebo - no active drug

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Days alive and out of hospital.
Timepoint [1] 0 0
induction of anaesthesia for cardiac surgery up to 90 days post operatively
Secondary outcome [1] 0 0
Correction of anemia following administration of trial drug to day of surgery measure by hemoglobin
Timepoint [1] 0 0
from administration of trial drug up to induction of anaesthesia for cardiac surgery up to 10 weeks
Secondary outcome [2] 0 0
Intensive care stay
Timepoint [2] 0 0
induction of anaesthesia for cardiac surgery to 30 days post operatively
Secondary outcome [3] 0 0
hospital stay
Timepoint [3] 0 0
induction of anaesthesia for cardiac surgery to 30 days post operatively
Secondary outcome [4] 0 0
Disability-free survival
Timepoint [4] 0 0
180 days from induction of anaesthesia for cardiac surgery
Secondary outcome [5] 0 0
90-day survival
Timepoint [5] 0 0
induction of anaesthesia for cardiac surgery up to 90 days post operatively
Secondary outcome [6] 0 0
units of allogeneic blood transfused
Timepoint [6] 0 0
induction of anaesthesia for cardiac surgery to discharge from hospital up to 30 days
Secondary outcome [7] 0 0
Quality of life
Timepoint [7] 0 0
induction of anaesthesia for cardiac surgery up to 180 days post operatively
Secondary outcome [8] 0 0
Cost-effectiveness
Timepoint [8] 0 0
From trial drug administration to 180 days from induction of anaesthesia for cardiac surgery
Secondary outcome [9] 0 0
Days alive and out of hospital.
Timepoint [9] 0 0
induction of anaesthesia for cardiac surgery up to 30 days post operatively

Eligibility
Key inclusion criteria
* Patients with anaemia (males Hb <130 g/L, females <120 g/L) undergoing elective cardiac surgery, and available to receive trial drug 1- 10 weeks prior to surgery
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Pregnancy
* Known hypersensitivity to study drug (ferric carboxymaltose or equivalent) or its excipients
* Known or suspected haemoglobinopathy/thalassaemia
* Bone marrow disease
* Haemochromatosis
* Renal dialysis
* Erythropoietin or IV iron in the previous 4 weeks

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 4
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Alfred Health - Melbourne
Recruitment postcode(s) [1] 0 0
3181 - Melbourne

Funding & Sponsors
Primary sponsor type
Government body
Name
Bayside Health
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
National Health and Medical Research Council, Australia
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Other
Name [2] 0 0
Monash University
Address [2] 0 0
Country [2] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Paul S Myles, MD
Address 0 0
Bayside Health
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Paul S Myles, MD
Address 0 0
Country 0 0
Phone 0 0
+61390762000
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Undecided
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.